TWEAK-Fn14 signaling activates myofibroblasts to drive progression of fibrotic kidney disease

Journal of the American Society of Nephrology

Volumn 27, Issue 12, 2016, Pages 3639-3652

  Gomez, Ivan G ^a,b   Roach, Allie M ^a,b   Nakagawa, Naoki ^b   Amatucci, Aldo ^a   Johnson, Bryce G ^a,b   Dunn, Kadeshia ^c   Kelly, Mark C ^c   Karaca, Gamze ^a   Zheng, Timothy S ^a   Szak, Suzanne ^a   Peppiatt Wildman, Claire M ^c   Burkly, Linda C ^a   Duffield, Jeremy S ^a,b  

^a BIOGEN   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G2A ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; TNFSF12 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; BLOOD VESSEL REACTIVITY; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOTHELIUM CELL; FIBROGENESIS; GENETIC MODEL; GLOMERULUS CAPILLARY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY SLICE; MOUSE; MYOFIBROBLAST; NONHUMAN; PERICYTE; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; VASOCONSTRICTION; ANIMAL; FIBROSIS; KIDNEY; KIDNEY DISEASES; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE PROGRESSION; FIBROSIS; KIDNEY; KIDNEY DISEASES; MICE; MYOFIBROBLASTS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 85021681946     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015111227     Document Type: Article

References (53)

1. Duffield JS: Cellular and molecularmechanisms in kidney fibrosis. JClin Invest 124: 2299-2306, 2014
2. Lin SL, Kisseleva T, Brenner DA, Duffield JS: Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173: 1617-1627, 2008
3. SchrimpfC, XinC, CampanholleG, Gill SE, StallcupW, Lin SL,DavisGE, Gharib SA, Humphreys BD, Duffield JS: Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol 23: 868-883, 2012
4. Grgic I, Krautzberger AM, Hofmeister A, Lalli M, DiRocco DP, Fleig SV, Liu J, Duffield JS, McMahon AP, Aronow B, Humphreys BD: Translational profiles of medullary myofibroblasts during kidney fibrosis. J Am Soc Nephrol 25: 1979-1990, 2014
5. LemosDR, Babaeijandaghi F, LowM,ChangCK, Lee ST, FioreD, Zhang RH, Natarajan A, Nedospasov SA, Rossi FM: Nilotinib reduces muscle fibrosis in chronicmuscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med 21: 786-794, 2015
6. Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L: Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. NatMed 18: 1262-1270, 2012
7. Kisseleva T, CongM, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, Evans SM, Dillmann W, Glass CK, Brenner DA:Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 109: 9448-9453, 2012
8. Puche JE, Lee YA, Jiao J, Aloman C, Fiel MI, Muñoz U, Kraus T, Lee T, Yee HF Jr, Friedman SL: A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology 57: 339-350, 2013
9. Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, Henderson JM, Ebert BL, Humphreys BD: Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 16: 51-66, 2015
10. Humphreys BD, Lin SL, Kobayashi A, Hudson TE,Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85-97, 2010
11. Hung C, Linn G, Chow YH, Kobayashi A, Mittelsteadt K, AltemeierWA, Gharib SA, Schnapp LM, Duffield JS: Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 188: 820-830, 2013
12. Göritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisén J: A pericyte origin of spinal cord scar tissue. Science 333: 238-242, 2011
13. Kida Y, Ieronimakis N, Schrimpf C, Reyes M, Duffield JS: EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury. J Am Soc Nephrol 24: 559-572, 2013
14. Lin SL, Chang FC, Schrimpf C, Chen YT, Wu CF, Wu VC, Chiang WC, Kuhnert F, Kuo CJ, Chen YM, Wu KD, Tsai TJ, Duffield JS: Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 178: 911-923, 2011
15. Kramann R, Fleig SV, Schneider RK, Fabian SL,DiRocco DP,Maarouf O, Wongboonsin J, Ikeda Y, Heckl D, Chang SL, Rennke HG, Waikar SS, Humphreys BD: Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. J Clin Invest 125: 2935-2951, 2015
16. Stefanska A, Eng D, Kaverina N, Pippin JW, Gross KW, Duffield JS, Shankland SJ:Cells of renin lineage express hypoxia inducible factor 2a following experimental ureteral obstruction. BMC Nephrol 17: 5, 2016
17. LigrestiG,Nagao RJ, Xue J, Choi YJ, Xu J, Ren S, Aburatani T, Anderson SK,MacDonald JW, Bammler TK, Schwartz SM,Muczynski KA, Duffield JS, Himmelfarb J, Zheng Y: A Novel Three-Dimensional Human Peritubular Microvascular System [published online ahead of print December 11, 2015]. J Am Soc Nephrol doi:10.1681/ASN.2015070747
18. Hammes HP: Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 37[Suppl 1]: 39-43, 2005
19. Olson LE, Soriano P: PDGFRb signaling regulates mural cell plasticity and inhibits fat development. Dev Cell 20: 815-826, 2011
20. Souma T, Nezu M, Nakano D, Yamazaki S, Hirano I, Sekine H, Dan T, Takeda K, Fong GH, Nishiyama A, Ito S,Miyata T, YamamotoM, Suzuki N: Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling. J Am Soc Nephrol 27: 428-438, 2015
21. Sanchez-Nino, MD, Benito-Martin, A, Goncalves, S, Sanz, AB, Ucero, AC, Izquierdo, MC, Ramos, AM, Berzal, S, Selgas, R, Ruiz-Ortega, M, Egido, J, Ortiz, A: TNF superfamily: A growing saga of kidney injury modulators. Mediators of inflammation 2010: 182958, 2010
22. McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MA, Macpherson AJ, McCoy KD, Pei Y, Novak L, Lee JY, Julian BA, Novak J, Ranger A, Gommerman JL, Browning JL: Mice overexpressing BAFF develop a commensal flora-dependent, IgAassociated nephropathy. J Clin Invest 121: 3991-4002, 2011
23. Wang J, Anders RA, Wu Q, Peng D, Cho JH, Sun Y, Karaliukas R, Kang HS, Turner JR, Fu YX: Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest 113: 826-835, 2004
24. Vincent FB, Morand EF, Schneider P, Mackay F: The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10: 365-373, 2014
25. Michaelson JS, Wisniacki N, Burkly LC, Putterman C: Role of TWEAK in lupus nephritis: A bench-to-bedside review. J Autoimmun 39: 130-142, 2012
26. Hodgin JB, Borczuk AC, Nasr SH, Markowitz GS, Nair V, Martini S, Eichinger F, Vining C, Berthier CC, Kretzler M, D'Agati VD: Amolecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol 177: 1674-1686, 2010
27. Woroniecka KI, Park AS,Mohtat D, Thomas DB, Pullman JM, Susztak K: Transcriptome analysis of human diabetic kidney disease. Diabetes 60: 2354-2369, 2011
28. Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, Perlman H, Wu L, Wu P, Michaelson JS, Burkly LC, Putterman C: Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol 26: 1053-1070, 2015
29. Hotta K, Sho M, Yamato I, Shimada K, Harada H, Akahori T, Nakamura S, Konishi N, Yagita H, Nonomura K, Nakajima Y: Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int 79: 179-188, 2011
30. Ucero AC, Benito-Martin A, Fuentes-Calvo I, Santamaria B, Blanco J, Lopez-Novoa JM, Ruiz-OrtegaM, Egido J, Burkly LC,Martinez-Salgado C, Ortiz A: TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta 1832: 1744-1755, 2013
31. Sanz AB, Sanchez-Niño MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, Ruiz-Ortega M, Selgas R, Egido J, Ortiz A: TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One 5: e8955, 2010
32. Yepes M: TWEAK and Fn14 in the Neurovascular Unit. Front Immunol 4: 367, 2013
33. Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7: 411-425, 2008
34. YilmazMI, Carrero JJ,Ortiz A,Martín-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM: Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 4: 1716-1723, 2009
35. Kennedy-Lydon TM, Crawford C, Wildman SS, Peppiatt-Wildman CM: Renal pericytes: regulators of medullary blood flow. Acta Physiol (Oxf) 207: 212-225, 2013
36. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C: STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43: D447-D452, 2015
37. Campbell S, Burkly LC, Gao HX, Berman JW, Su L, Browning B, Zheng T, Schiffer L, Michaelson JS, Putterman C: Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 176: 1889-1898, 2006
38. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348: 2543-2556, 2003
39. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW: ASCEND Study Group: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370: 2083-2092, 2014
40. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, DonohueM, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB: Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22: 1144-1151, 2011
41. Grattendick KJ, Nakashima JM, Feng L, Giri SN,Margolin SB: Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in mediumand TNF-alpha associatedwith the cell in vitro. Int Immunopharmacol 8: 679-687, 2008
42. Tsushima K,Osawa T, Yanai H,Nakajima A, Takaoka A, Manabe I,Ohba Y, Imai Y, Taniguchi T, Nagai R: IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension. FASEB J 25: 1531-1543, 2011
43. Jiang DS, Bian ZY, Zhang Y, Zhang SM, Liu Y, Zhang R, Chen Y, YangQ, Zhang XD, Fan GC, Li H: Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 61: 1193-1202, 2013
44. Maahs DM, Siwy J, Argilés A, Cerna M, Delles C, Dominiczak AF, Gayrard N, Iphöfer A, Jänsch L, Jerums G, Medek K, Mischak H, Navis GJ, Roob JM, Rossing K, Rossing P, Rychlík I, Schiffer E, Schmieder RE, Wascher TC, Winklhofer-Roob BM, Zimmerli LU, Zürbig P, Snell-Bergeon JK: Urinary collagen fragments are significantly altered in diabetes: A link to pathophysiology. PLoS One 5: e13051, 2010
45. Veidal SS, Karsdal MA, Vassiliadis E, Nawrocki A, Larsen MR, Nguyen QH, Hägglund P, Luo Y, Zheng Q, Vainer B, Leeming DJ: MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS One 6: e24753, 2011
46. Naugle JE, Olson ER, Zhang X, Mase SE, Pilati CF, Maron MB, Folkesson HG, Horne WI, Doane KJ, Meszaros JG: Type VI collagen induces cardiac myofibroblast differentiation: implications for postinfarction remodeling. Am J Physiol Heart Circ Physiol 290: H323-H330, 2006
47. Keene DR, Engvall E, Glanville RW: Ultrastructure of type VI collagen in human skin and cartilage suggests an anchoring function for this filamentous network. J Cell Biol 107: 1995-2006, 1988
48. Kielty CM, Whittaker SP, Grant ME, Shuttleworth CA: Type VI collagen microfibrils: evidence for a structural association with hyaluronan.JCell Biol 118: 979-990, 1992
49. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM: Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 43: 662-673, 2010
50. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, Winkles JA, Michaelson JS, Allaire N, Schneider P, Scott ML, Hsu YM, Yagita H, Flavell RA, Miller JB, Burkly LC, Zheng TS: TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 25: 5826-5839, 2006
51. Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, Ren S, NakagawaN, Xin C,Newitt R, Pandya S, Xia TH, Liu X, BorzaDB,Grafals M, Shankland SJ, Himmelfarb J, Portilla D, Liu S, Chau BN, Duffield JS: Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 125: 141-156, 2015
52. Lin SL, Li B, Rao S, Yeo EJ, Hudson TE, Nowlin BT, Pei H, Chen L, Zheng JJ, Carroll TJ, Pollard JW, McMahon AP, Lang RA, Duffield JS: MacrophageWnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci U S A 107: 4194-4199, 2010
53. Crawford C, Kennedy-Lydon T, Sprott C,Desai T, Sawbridge L,Munday J, Unwin RJ, Wildman SS, Peppiatt-Wildman CM: An intact kidney slice model to investigate vasa recta properties and function in situ. Nephron, Physiol 120: 17-31, 2012